

PAD VOLUME I

Table of Contents

INTRODUCTION	7
THE DISEASE	7
SYMPTOMS AND CONSEQUENCES	8
INTERMITTENT CLAUDICATION IS UNCOMMON	8
PAD IS NOT ASYMPTOMATIC	10
MORTALITY	11
<i>Heart Attack and Stroke—The Main Causes of Death</i>	11
<i>High Five- and 10-Year Mortality</i>	11
AN INDICATOR OF SILENT CARDIOVASCULAR AND CEREBROVASCULAR	
DISEASE	13
PAD SEVERITY PREDICTS CARDIOVASCULAR MORBIDITY AND MORTALITY	14
RISK FACTORS	15
<i>Age</i>	16
<i>Smoking</i>	17
<i>Diabetes</i>	17
<i>Hypertension</i>	18
<i>Cholesterol</i>	18
<i>Race</i>	19
MULTIPLE RISK FACTORS INCREASE THE RISK	19
WOMEN AND PAD	20
DIAGNOSIS	21
DISEASE SEVERITY ASSOCIATED WITH LOWER ABI	21
PREVALENCE	22
PAD IS A SIGNIFICANT MARKET OPPORTUNITY—14 MILLION PEOPLE	23
<i>Estimated Prevalence Based On Diabetic Population</i>	23
PAD TO INCREASE WITH THE GRAYING OF AMERICA	25
PAD PREVALENCE COMPARED TO OTHER SERIOUS DISEASES	25
PAD IS UNDERDIAGNOSED	26
<i>Less Than 20% of PAD Patients Estimated to Have Been Diagnosed</i>	27
<i>New Education and Awareness Programs Leading to Increased Numbers Diagnosed</i>	29
TREATMENTS	30
<i>Risk Factor Modification</i>	30
<i>Supervised Exercise Program</i>	30
<i>Drug Therapy</i>	31
ATHEROSCLEROSIS—AN INFLAMMATORY DISEASE	31
<i>Vulnerable Plaque</i>	33
<i>Blood Clots</i>	33
ANTIHYPERTENSIVES	34
<i>ACE Inhibitors and Angiotensin Receptor Blockers (Antagonists)</i>	34
<i>Angiotensin Receptor Blockers</i>	36
DIABETIC PATIENTS	36
REDUCING THE RISK OF BLOOD CLOTS	37
LIPID REDUCTION	39

<i>Statins</i>	39
Muscle Myopathy	40
Heart Protection Study	41
<i>Zetia—A New Class of Cholesterol Medication</i>	41
<i>Other Lipid-Lowering Agents—Fibrates and Bile Acid Sequestrants</i>	42
<i>Niacin</i>	43
CHOLESTEROL REDUCTION AND VASCULAR REMODELING	44
PAD DYSLIPIDEMIA SIMILAR TO ATHEROGENIC DYSLIPIDEMIA	46
NEW OPPORTUNITIES—TARGETED DRUG THERAPY FOR PAD	47
NEW RISK FACTORS	49
<i>Lipoprotein (a)</i>	49
<i>Homocysteine</i>	50
<i>Inflammatory Factors</i>	50
<i>C-Reactive Protein</i>	51
CLAUDICATION THERAPIES	52
PROGRESSION OF PAD AND PERCENTAGE OF PATIENTS NEEDING TREATMENT	53
PAD UNDERTREATED	54
LARGE POTENTIAL MARKETS FOR DRUG THERAPY	55
<i>Market for Claudication Therapy</i>	59
<i>Market for Antihypertensives</i>	59
<i>Market for Cholesterol-Lowering Therapy</i>	62
<i>Market for Antiplatelets</i>	65
VALUATION TABLE	69
COMPANY INFORMATION AND FINANCIAL DATA (ALPHABETICAL LIST)	71
REFERENCES	97
LIST OF STUDIES/ACRONYMS	107
INDEX OF TABLES AND FIGURES	111
GLOSSARY	117
TRADEMARKS	131
DISCLOSURE STATEMENT	133
CONTACT INFORMATION	135